A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

NCT01248455 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
9
Enrollment
NIH
Sponsor class

Stopped Lack of patients meeting the defined primary obj. (50% decline in M-protein).

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)